OOIR: Observatory of International Research

Papers

(The H4-Index of Nature Reviews Rheumatology is 58. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
No benefit from adding MTX to ustekinumab	525
Bimekizumab effective across the axSpA spectrum	455
SLC26A2 deficiency, matrix stiffness and mechanotransduction linked in osteoporosis	342
Genome-wide mutagenesis reported in systemic sclerosis	302
The role of the patient in rheumatology	277
Reply to ‘Potential benefit of anticoagulation in Behçet syndrome’	232
A role for TGFβ and EBV in MIS-C pathogenesis	218
Rheumatic diseases on the rise	199
Osteoarthritis as a systemic disease	181
Biological and clinical roles of IL-18 in inflammatory diseases	180
Towards better management of sterile bone inflammation	168
New drug formulation reduces bone loss	162
To choose or not? The value of discrete-choice experiments in rheumatology	160
The value of comparative efficacy studies in informing rheumatology guidelines	160
The 2022 ACR vaccination guideline: a call-to-action	157
Appraising the evolving landscape of protease inhibition in osteoarthritis	150
MIS-C: myths have been debunked, but mysteries remain	150
Imbalance of threat and soothing systems in fibromyalgia: rephrasing an established mechanistic model?	146
FOXP3 splice variant is associated with autoimmune disease	137
Down syndrome: insights into autoimmune mechanisms	135
Urchin-like nanoparticles for miRNA therapy of OA	131
Inflammation across tissues: can shared cell biology help design smarter trials?	131
Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician	126
Addressing the challenge of global delays in diagnosis and treatment of systemic lupus erythematosus	122
Low-dose glucocorticoids benefit seniors with RA	120

Co-trimoxazole reduces mortality in anti-MDA5-DM	119
Immune reset and immune retune: approaching cure?	114
Fibroblast TGFβ drives treatment-refractory RA	113
Wnt-induced IGF1 drives OA	108
A direct link between SARS-CoV-2 and bone loss	108
COPA syndrome spans multiple organs but is defined by STING in the lung	108
Biologics in rheumatoid arthritis: a lifetime treatment or possibility of drug holidays?	108
Author Correction: Proposals for the rheumatological use of JAK inhibitors	104
Calprotectin tracks tocilizumab-treated RA	100
Fumarate drives interferon release in systemic sclerosis monocytes	99
Pain in systemic lupus erythematosus: emerging insights and paradigms	95
S100A4 inhibition targets fibrosis in SSc	95
Publisher Correction: Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician	91
Low back pain is a growing concern	90
Distinct mucosal endotypes as initiators and drivers of rheumatoid arthritis	87
Rheumatic diseases and metabolism: where centre and periphery meet	85
Sexual dimorphism in the prevalence, manifestation and outcomes of axial spondyloarthritis	80
Rheumatology in the digital health era: status quo and quo vadis?	79
Guiding ILD management in systemic autoimmune rheumatic diseases	79
Targeting the IVD clock to halt degeneration	76
Which DMARD for ICI-associated arthritis?	75
Phase III trial of telitacicept in SLE	71
A path towards personalized medicine for autoinflammatory and related diseases	68
Chimeric receptors broaden the therapeutic landscape for autoimmune disease	66
Publisher Correction: Recent advances in the diagnosis and management of neuropsychiatric lupus	66
Cell-free DNA fragmentation signatures link cancer and autoimmunity	66
Erosive cargo from synovial fibroblasts	65
Insights into IVDD pathogenesis in 2024	62
ERAP1 and the return of the UPR in ankylosing spondylitis	60
Macrophage-coated nanocarriers for gouty arthritis	59
CAR T cells induce drug-free SLE remission	59
RA risk from occupational inhalation	58
International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative	58